• 18-70 years old;

• Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma;

• 2018 FIGO Stage Ib3, II, and IIIC1

• Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses)

• ECOG score 0-2

• Life expectancy greater than 6 months

• Ability to remain lying down for more than 30 minutes

• Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form

• Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5\*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal

⁃ Must complete baseline assessments and investigations required before treatment before enrolment

⁃ be eligible for regular follow-up